Vaidya Sane Q2 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Published 26 Aug 2026 | Healthcare Equipment & Supplies | Market Cap: ₹179 Cr
FY '26 expected revenue: INR 115-120 crores. FY '26 revenue expected at INR 115-120 crores, with 20% growth and EBITDA margins around 17-18%.
From Vaidya Sane's Q2 FY26 earnings-call transcript · updated 26 Aug 2026.
Price
₹179
Market Cap
₹179 Cr
P/E Ratio
19.9
Revenue Rank
Margin Rank
How does Vaidya Sane rank in Healthcare Equipment & Supplies?
Compare Vaidya Sane against every Healthcare Equipment & Supplies company this quarter on revenue, margins and earnings-call signals.
📊 Revenue & Sales Performance
Rank 2- →FY '26 expected revenue: INR 115-120 crores.
- →FY '27 projected sales: Around INR 180 crores; INR 50-55 crores from hospitals, INR 125-135 crores from clinics, with potential to surpass this figure.
- →FY '28 sales target: INR 280 crores planned, with aim to surpass and possibly reach INR 320-350 crores.
- →EBITDA margins expected to increase to 30%-35% by FY '28 if INR 280 crore turnover is achieved.
- →Revenue growth drivers include increased patient footfall in clinics, expansion of hospital bed capacity from current 110 beds to 350+ beds by FY '28.
- →Scale-up of Madhavprash sales from 15,000-20,000 units/month currently to target of 1 lakh units/month in next 24 months.
- →Expansion plans include adding 6 more hospitals mostly in Gujarat, Maharashtra, Rajasthan, and potential franchise hospital upgrades.
- →Overall growth focus on clinics, hospitals, food/nutritional products, and wellness centers.
📈 Profitability & Margins
Rank 1- →FY '26 revenue expected at INR 115-120 crores, with 20% growth and EBITDA margins around 17-18%.
- →EBITDA margin targeted to steadily increase, aiming for ~20% by FY '28.
- →PAT margins anticipated to rise to about 10-12% by FY '28.
- →By FY '28, revenue potential estimated at INR 280 crores or more, possibly reaching INR 320-350 crores, with roughly 30-35% EBITDA margin.
- →EBITDA anticipated to grow 1.5x to 2x by FY '28 compared to current, with EBITDA above 30%.
- →EPS growth aligned with revenue and profit increases; EPS was INR 4.56 in H1 FY '26, expected to improve with scaling.
- →Confidence in maintaining operational discipline, sustainable growth, and expanding patient base to drive earnings.
🏗️ Capital Expenditure Plans
Yes💰 Fundraising & Capital Structure
Yes- →The company has issued 40 lakh preferential warrants to institutional investors, pending NSE approval for 25% payment to be received.
- →No new equity fundraising announced beyond this; the receipt of funds depends on regulatory approval.
- →No mention of fresh debt-raising plans in the current discussion or future outlook.
- →Existing capital raise proceeds from warrants are primarily earmarked for hospital expansions (Khopoli and Nagpur).
- →The company is focusing on internal cash flow generation to fund growth, indicating limited reliance on external debt.
📋 Order Book & Pipeline
YesKey Metrics
Revenue
Margin
Capex
Fundraise
Order Book
Frequently Asked Questions
What were Vaidya Sane Q2 FY26 results?
FY '26 expected revenue: INR 115-120 crores. FY '26 revenue expected at INR 115-120 crores, with 20% growth and EBITDA margins around 17-18%.
What is Vaidya Sane share price analysis?
Vaidya Sane currently shows a moderate growth signal based on ranking data. The stock trades at a P/E of 19.9 with a market cap of ₹179 Cr. Investors should review the full earnings analysis for detailed insights.
Is Vaidya Sane planning capital expenditure?
Current/future CAPEX plans:** - Expansion of hospitals at Khopoli (100 extra beds) and Nagpur (80 beds) with an estimated investment of INR 25-30 crores. - Vadodara hospital expansion on a rental model; no construction CAPEX expected but installation costs applicable. - Ongoing construction started for Khopoli hospital expansion; Nagpur hospital CAPEX to commence in 3-4 months. - Capacity expansion at Nagpur hospital adding 5 beds, investment approx.
Keep Vaidya Sane on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.